NZ598601A - Dosage regimen for administering an epcamxcd3 bispecific antibody - Google Patents
Dosage regimen for administering an epcamxcd3 bispecific antibodyInfo
- Publication number
- NZ598601A NZ598601A NZ598601A NZ59860110A NZ598601A NZ 598601 A NZ598601 A NZ 598601A NZ 598601 A NZ598601 A NZ 598601A NZ 59860110 A NZ59860110 A NZ 59860110A NZ 598601 A NZ598601 A NZ 598601A
- Authority
- NZ
- New Zealand
- Prior art keywords
- dose
- antibody
- epcamxcd3 bispecific
- formulated
- time
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24365109P | 2009-09-18 | 2009-09-18 | |
| EP09170715 | 2009-09-18 | ||
| US34414710P | 2010-06-01 | 2010-06-01 | |
| EP10164596 | 2010-06-01 | ||
| PCT/EP2010/063795 WO2011033105A1 (en) | 2009-09-18 | 2010-09-20 | Dosage regimen for administering an epcamxcd3 bispecific antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ598601A true NZ598601A (en) | 2014-05-30 |
Family
ID=43127167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ598601A NZ598601A (en) | 2009-09-18 | 2010-09-20 | Dosage regimen for administering an epcamxcd3 bispecific antibody |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20120244161A1 (enExample) |
| EP (1) | EP2477653A1 (enExample) |
| JP (1) | JP2013505223A (enExample) |
| KR (1) | KR20120083359A (enExample) |
| CN (1) | CN102711825A (enExample) |
| AU (1) | AU2010297258A1 (enExample) |
| BR (1) | BR112012008345A2 (enExample) |
| CA (1) | CA2774732A1 (enExample) |
| IL (1) | IL218637A0 (enExample) |
| IN (1) | IN2012DN03172A (enExample) |
| MX (1) | MX2012003175A (enExample) |
| NZ (1) | NZ598601A (enExample) |
| RU (1) | RU2012115480A (enExample) |
| SG (2) | SG10201405434VA (enExample) |
| WO (1) | WO2011033105A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012158818A2 (en) | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| AU2012350429A1 (en) | 2011-12-09 | 2013-07-11 | Amgen Research (Munich) Gmbh | Prevention of adverse effects caused by EpCAMxCD3 bispecific antibodies |
| GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| FI3889173T3 (fi) | 2013-02-15 | 2023-10-02 | Bioverativ Therapeutics Inc | Optimoitu tekijä viii:n geeni |
| JP6499087B2 (ja) | 2013-02-26 | 2019-04-10 | ロシュ グリクアート アーゲー | 二重特異性ｔ細胞活性化抗原結合分子 |
| AU2015204766B2 (en) * | 2014-01-08 | 2020-08-13 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted therapy for small cell lung cancer |
| WO2016004113A1 (en) | 2014-06-30 | 2016-01-07 | Biogen Ma Inc. | Optimized factor ix gene |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| EP3903818A1 (en) * | 2015-11-19 | 2021-11-03 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| KR20180118659A (ko) | 2016-02-01 | 2018-10-31 | 바이오버라티브 테라퓨틱스 인크. | 최적화된 viii 인자 유전자 |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| JP7034489B2 (ja) | 2016-03-15 | 2022-03-14 | アイタブメッド （エイチケイ） リミテッド | 多重特異性Ｆａｂ融合タンパクおよびその使用 |
| WO2017167350A1 (en) * | 2016-03-30 | 2017-10-05 | Horst Lindhofer | Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract |
| EP3409322A1 (en) * | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
| WO2019051102A2 (en) | 2017-09-08 | 2019-03-14 | Maverick Therapeutics, Inc. | Constrained conditionally activated binding proteins |
| US12460000B2 (en) | 2018-09-07 | 2025-11-04 | Itabmed (Hk) Limited | Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof |
| WO2020132810A1 (en) | 2018-12-24 | 2020-07-02 | Generon (Shanghai) Corporation Ltd. | Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof |
| WO2020181140A1 (en) | 2019-03-05 | 2020-09-10 | Maverick Therapeutics, Inc. | Constrained conditionally activated binding proteins |
| US12403164B2 (en) | 2019-09-30 | 2025-09-02 | Bioverativ Therapeutics Inc. | Lentiviral vector formulations |
| KR20230074703A (ko) | 2020-06-24 | 2023-05-31 | 바이오버라티브 테라퓨틱스 인크. | 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법 |
| JP2024540461A (ja) * | 2021-11-19 | 2024-10-31 | 武▲漢▼友芝友生物制▲薬▼股▲ふん▼有限公司 | 二重特異性抗体及びその用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
| ZA200601699B (en) | 2003-10-16 | 2007-05-30 | Micromet Ag | Multispecific deimmunized CD3-binders |
| ES2417065T3 (es) * | 2005-04-26 | 2013-08-05 | Trion Pharma Gmbh | Combinación de anticuerpos con glucocorticoides para el tratamiento del cáncer |
-
2010
- 2010-09-20 SG SG10201405434VA patent/SG10201405434VA/en unknown
- 2010-09-20 JP JP2012529298A patent/JP2013505223A/ja active Pending
- 2010-09-20 RU RU2012115480/15A patent/RU2012115480A/ru not_active Application Discontinuation
- 2010-09-20 EP EP10755167A patent/EP2477653A1/en not_active Withdrawn
- 2010-09-20 US US13/496,836 patent/US20120244161A1/en not_active Abandoned
- 2010-09-20 CA CA2774732A patent/CA2774732A1/en not_active Abandoned
- 2010-09-20 BR BR112012008345A patent/BR112012008345A2/pt not_active IP Right Cessation
- 2010-09-20 CN CN2010800523771A patent/CN102711825A/zh active Pending
- 2010-09-20 NZ NZ598601A patent/NZ598601A/en not_active IP Right Cessation
- 2010-09-20 AU AU2010297258A patent/AU2010297258A1/en not_active Abandoned
- 2010-09-20 SG SG2012016044A patent/SG179027A1/en unknown
- 2010-09-20 IN IN3172DEN2012 patent/IN2012DN03172A/en unknown
- 2010-09-20 WO PCT/EP2010/063795 patent/WO2011033105A1/en not_active Ceased
- 2010-09-20 KR KR1020127007677A patent/KR20120083359A/ko not_active Withdrawn
- 2010-09-20 MX MX2012003175A patent/MX2012003175A/es not_active Application Discontinuation
-
2012
- 2012-03-14 IL IL218637A patent/IL218637A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG10201405434VA (en) | 2014-10-30 |
| CA2774732A1 (en) | 2011-03-24 |
| WO2011033105A1 (en) | 2011-03-24 |
| KR20120083359A (ko) | 2012-07-25 |
| US20120244161A1 (en) | 2012-09-27 |
| JP2013505223A (ja) | 2013-02-14 |
| BR112012008345A2 (pt) | 2016-08-09 |
| IL218637A0 (en) | 2012-05-31 |
| RU2012115480A (ru) | 2013-10-27 |
| CN102711825A (zh) | 2012-10-03 |
| AU2010297258A1 (en) | 2012-03-29 |
| EP2477653A1 (en) | 2012-07-25 |
| IN2012DN03172A (enExample) | 2015-09-25 |
| SG179027A1 (en) | 2012-04-27 |
| MX2012003175A (es) | 2012-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX354371B (es) | Régimen de dosificación para administrar un anticuerpo biespecífico cd19xcd3 a pacientes en riesgo de efectos adversos potenciales. | |
| SG179027A1 (en) | Dosage regimen for administering an epcamxcd3 bispecific antibody | |
| MY159353A (en) | Pirfenidone treatment for patients with atypical liver function | |
| WO2012079093A3 (en) | Dosage and administration of bispecific scfv conjugates | |
| ME02662B (me) | Niskofrekventna terapija glatiramer acetatom | |
| WO2009033762A3 (en) | Use of endothelin-3 as a therapeutic agent | |
| NZ606993A (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| SG179204A1 (en) | Dosage regimen for administering a cd19xcd3 bispecific antibody | |
| EP2216024A3 (en) | Use of Ranolazine for the treatment of cardiovascular diseases | |
| UA105191C2 (ru) | Лечение пирфенидоном пациентов с атипической функцией печени | |
| WO2009040084A3 (en) | Use of a peptide as a therapeutic agent | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| ATE553772T1 (de) | Verwendung von lvv-hämorphin-6 und optional af12198 als therapeutische(s) mittel | |
| IL196425A0 (en) | Pharmaceutical compositions containing ibuprofen and famotidine | |
| WO2007012019A3 (en) | Medicaments containing famotidine and ibuprofen and administration of same | |
| MX2009010268A (es) | Reduccion de eventos adversos despues de intervencion percutanea mediante el uso de un antagonista del receptor de trombina. | |
| NZ598465A (en) | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin | |
| WO2008008882A3 (en) | Glucocorticoid receptor modulator and methods of use | |
| RU2013120345A (ru) | Новые способы лечения инфекции, вызванной вирусом гепатита с | |
| TN2016000179A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. | |
| MY174442A (en) | Treating critically ill patients with intravenous ibuprofen | |
| RU2013148539A (ru) | Алиспоривир для лечения инфекции вируса гепатита с | |
| NZ767902B2 (en) | Methods of treating ulcerative colitis | |
| NZ733365A (en) | Dosage regimen for madcam antagonists | |
| NZ726636A (en) | Novel compounds and compositions for targeting cancer stem cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 SEP 2015 BY CPA GLOBAL Effective date: 20141031 |
|
| LAPS | Patent lapsed |